eFigure 1. Definition of the NAT-group and the IFN1- and IFN2-subgroup. The initial cohort analyzed for anti-JCV antibodies consisted of MS patients (NAT-group) tested at t3 (just before the first infusion with natalizumab (NAT)) and t4 (during NAT therapy). In a proportion of the same patients, additional earlier time points prior to NAT therapy (t1, t2) during the preceding therapy with an interferon beta formulation (IFN) were analyzed, depending on availability of these samples. For these patients, subgroups were defined as the following: for the largest, the IFN1-subgroup, antibody levels at t1 were compared with the levels at t3, and for the IFN2-subgroup - in order to have a subgroup with similar time between sampling compared with the NAT-group - antibody levels at t1 were compared with the levels at t2.